parkinson's disease retatrutide clinical trial retatrutide parkinson's disease clinical trial Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson's disease: Cell-150cent Liraglutide once daily versus placebo

Abbreviations 5-HIAA: 5-Hydroxyindoleacetic acid 5-HT: Serotonin (5-hydroxytryptamine) BBB: Bloodbrain barrier BDNF: Brain-derived neurotrophic factor cAMP: Cyclic adenosine monophosphate CRH: Corticotropin-releasing hormone CRP: C-reactive protein DPP-4: Dipeptidyl peptidase-4 GABA: Gamma aminobutyric acid GLP-1: Glucagon-like peptide-1 GLP-1R: Glucagon-like-1 peptide receptor GLP-1RA: Glucagon-like-1 peptide receptor agonist HPA: Hypothalamicpituitaryadrenal axis Icv : Intracerebroventricular Ip : Intraperitoneal IL-1: Interleukin-1 beta IL-6: Interleukin-6 NF-B: Nuclear factor kappa-light-chain-enhancer of activated B cells NTS: Nucleus tractus solitarius PKA: Protein kinase A PPG: Preproglucagon PVN: Paraventricular nucleus SCFA: Short chain fatty acid T2DM: Type 2 diabetes mellitus TNF-: Tumor necrosis factor alpha VTA: Ventral tegmental area References Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al

(2023) Phase 2 Retatrutide Trial, NEJM (PubMed) Coskun et al

Some plans may also cover these drugs for people with a BMI of 27 or higher if they also have other weight-related health conditions such as type 2 diabetes, high blood pressure, or high cholesterol

Table of Contents : What Are GLP-1 Agonists